CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.

ABSTRACT:

Background

Soft tissue sarcomas (STS) are heterogeneous and pro-metastatic tumors. Identification of accurate prognostic factors and novel therapeutic targets are crucial. CSPG4 is a cell surface proteoglycan with oncogenic functions. It recently emerged as a potential target for immunotherapy, including cell therapy based on CSPG4-specific chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CSPG4-CAR.CIKs) in STS. However, expression of CSPG4 is poorly known in STS so far.

Methods

We analyzed CSPG4 gene expression in 1378 localized STS clinical samples, and searched for correlations with clinicopathological data, including disease-free survival (DFS), and with tumor immune features.

Results

CSPG4 expression was heterogeneous across samples

SUBMITTER: Boudin L 

PROVIDER: S-EPMC9552405 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature